PT - JOURNAL ARTICLE AU - Andrew A. Davis AU - Wade T. Iams AU - David Chan AU - Michael S. Oh AU - Robert W. Lentz AU - Neil Peterman AU - Alex Robertson AU - Abhik Shah AU - Rohith Srivas AU - Timothy Wilson AU - Nicole Lambert AU - Peter George AU - Becky Wong AU - Haleigh Wood AU - Jason Close AU - Ayse Tezcan AU - Ken Nesmith AU - Haluk Tezcan AU - Young Kwang Chae TI - Early assessment of molecular progression and response by whole-genome circulating tumor DNA in advanced solid tumors AID - 10.1101/19002550 DP - 2019 Jan 01 TA - medRxiv PG - 19002550 4099 - http://medrxiv.org/content/early/2019/11/25/19002550.short 4100 - http://medrxiv.org/content/early/2019/11/25/19002550.full AB - Treatment response assessment for patients with advanced solid tumors is complex and existing methods require greater precision. Current guidelines rely on imaging, which has known limitations, including the time required to show a deterministic change in target lesions. Serial changes in whole-genome (WG) circulating tumor DNA (ctDNA) were used to assess response or resistance to treatment early in the treatment course. 96 patients with advanced cancer were prospectively enrolled (91 analyzed and 5 excluded), and blood was collected before and after initiation of a new, systemic treatment. Plasma cell-free DNA libraries were prepared for either WG or WG bisulfite sequencing. Longitudinal changes in the fraction of ctDNA were quantified to retrospectively identify molecular progression (MP) or major molecular response (MMR). Study endpoints were concordance with first follow-up imaging (FFUI) and stratification of progression-free survival (PFS) and overall survival (OS). Patients with MP (n=13) had shorter PFS (median 62d vs. 310d) and OS (255d vs. not reached). Sensitivity for MP to identify clinical progression was 54% and specificity was 100%. MP calls were from samples taken a median of 28d into treatment and 39d before FFUI. Patients with MMR (n=27) had longer PFS and OS compared to those with neither call (n=51). Molecular response assessment can potentially enable early switching to potentially effective therapies, therefore minimizing side effects and costs associated with additional cycles of ineffective treatment. MMR may present a novel endpoint to target to improve long-term patient outcomes.Competing Interest StatementAAD - travel support (Menarini Silicon Biosystems). WTI - advisory board (Genentech), honoraria (Outcomes Insights), investigator meeting (EMD Serono). NP, AR, AS, RS, TW, NL, PG, BW, HW, JC, AT, KN, & HT - current or previous employees of and ownership interest in Lexent Bio. AR, AS, TW, & KN - previous employees of and ownership interest in Counsyl. TW - previous employee and ownership interest in Illumina and Biocept. NL - previous employee of and ownership interest in Sequenom. PG - previous employee of and ownership interest in Hologic. YKC - research grant (Abbvie, BMS, Biodesix, Lexent Bio, Freenome), honoraria/advisory board (Roche/Genentech, AstraZeneca, Foundation Medicine, Counsyl, Neogenomics, Guardant Health, Boehringer Ingelheim, Biodesix, Immuneoncia, Lilly Oncology, Merck, Takeda). DC, MSO, & RWL - none.Clinical TrialThis is an observational study without any intervention, registered under NCT02288754.Funding StatementThis study was supported by Lexent Bio, Inc.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.YesI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesData in this manuscript is represented in the methods, results, and supplementary information.